1.Chemotherapy for lung cancer At present, chemotherapy for lung cancer is still the main method of lung cancer treatment, and the two-drug combination regimen of three-generation chemotherapy drugs combined with platinum is the most dominant regimen. The three generations of chemotherapy drugs are mainly vincristine (N), paclitaxel (T), gemcitabine (G), docetaxel (D), and pemetrexed. The main platinum drugs are cisplatin (P) and carboplatin (C). ECOG1594 conducted a comparative study of four regimens, TP, GP, DP, and TC, and did not find significant differences between the four regimens in terms of prolonging overall survival (OS), but the one-year survival rate of 36% for the GP regimen and 4.2 months for TTP was slightly superior, so the GP regimen became the first-line treatment for non-small cell lung cancer. TAX317 and TAX320 studied docetaxel 75 mg/m2 with best supportive care; docetaxel 75 mg/m2, docetaxel 100 mg/m2 with vincristine and isocyclophosphamide in second-line treatment of non-small cell lung cancer, respectively, and the results showed that the one-year survival rates of docetaxel 75 mg/m2 in the two trials reached 37% and 32%, respectively. The JMEI study compared remission rates, median survival time and one-year survival rates between pemetrexed and docetaxel for second-line treatment of non-small cell lung cancer and showed no significant differences between the two in any of the study endpoints, making pemetrexed monotherapy the second-line treatment of choice. found that pemetrexed in combination with carboplatin was superior to gemcitabine in combination with carboplatin (OS of 21.2 months) in patients with non-squamous carcinoma (17.7 months), whereas the opposite was true for patients with squamous carcinoma, and this study was the beginning of the selection of chemotherapy regimens based on tissue type. Therefore, for squamous carcinoma, gemcitabine plus platinum and docetaxel plus platinum regimens are now commonly used, while for non-squamous non-small cell lung cancers such as adenocarcinoma, pemetrexed plus platinum, gemcitabine plus platinum and docetaxel plus platinum are commonly used. The first-line chemotherapy regimen for small cell lung cancer remains etoposide in combination with platinum-based agents. The remission rate for limited stage small cell lung cancer combined with radiotherapy can reach 70% to 80%, and the median survival is 14 to 20 months. Radiotherapy for lung cancer For early stage non-small cell lung cancer (stage I, II), radical radiotherapy can be performed, combined with the use of stereotactic (SBRT) technology for early inoperable or unwilling cases is a curable means. For locally advanced (IIIA and IIIB) non-small cell lung cancer, conventional radiotherapy is less effective. In the past 20 years, the application of precise radiotherapy techniques such as intensity modulated conformal radiotherapy has improved the efficacy, and the organic combination of chemotherapy and radiotherapy has also improved the survival rate. Small cell lung cancer has better efficacy in radiotherapy, so systemic chemotherapy combined with local radiotherapy has become the standard treatment for limited stage small cell lung cancer. In addition, prophylactic brain irradiation (PCI) is advocated for small cell lung cancer patients with effective chemotherapy, regardless of limited or extensive stage, which can effectively prolong survival. 3.Anti-angiogenic therapy for lung cancer The growth of solid tumors is inseparable from angiogenesis and growth, therefore, anti-angiogenic therapy has become a new strategy for the treatment of lung cancer in recent years. The ECOG4599 study published in 2006 showed that the DC regimen combined with bevacizumab could improve the overall survival from 10.2 months to 12.5 months (p<0.007), so the US FDA approved bevacizumab combined with platinum-containing two-drug regimen as a non-small cancer treatment. The two-drug combination of bevacizumab and platinum was approved by the US FDA as the first-line treatment option for NSCLC. The recombinant human endothelial inhibitor is modified on the basis of the parent endothelial inhibitor, which is more stable, with longer half-life and increased biological activity. 4.Molecular targeted therapy for lung cancer Among the molecular targeted drugs for lung cancer, the main target is epidermal growth factor receptor (EGFR), which can be divided into small-molecule compounds and large-molecule monoclonal antibodies. Small-molecule compounds mainly block the EGFR signaling pathway by blocking EGFR intracellular tyrosine kinase (TK), whose representative drugs are gefitinib and erlotinib. The ISEL study published in 2008 demonstrated that gefitinib significantly prolonged median survival compared to placebo in Asian patients with refractory lung cancer (9.5 vs. 5.5 months, p=0.01), and therefore gefitinib was approved as a second- or third-line treatment in many Asian countries. The INTEREST study compared gefitinib with the second-line standard drug docetaxel in patients who failed first-line treatment and showed no significant differences in overall survival, 1-year survival, or efficiency, thus establishing gefitinib as the second-line standard drug. Further subgroup analysis showed that in the gefitinib group, those with positive EGFR mutations were significantly more effective than those with negative mutations (71.2% vs. 1.1%), demonstrating that selected patients can be treated with gefitinib in the first line. The FLEX study, published in 2008, compared the overall survival of patients with primary advanced non-small cell lung cancer on an NP regimen with or without cetuximab and showed that Overall survival in the combined cetuximab group was 11.3 months versus 10.1 months in the NP group (p=0.044). Another important target for NSCLC is the EML4-ALK fusion gene. The FDA approved crizotinib as a first-line treatment for EML4-ALK fusion-positive NSCLC in August 2011, which will bring hope to some EML4-ALK fusion-positive patients.